更新于：2024-11-04
Fosfomycin Sodium
磷霉素钠
更新于：2024-11-04
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C3H7Na2O4P |
InChIKeyXKMSQWKOGZTAQM-JSTPYPERSA-N |
CAS号26016-99-9 |
关联
42
项与 磷霉素钠 相关的临床试验COMPARISON OF NITROFURANTOIN WITH FOSFOMYCIN in TREATING CYSTITIS IN WOMEN
Therapeutic Strategies for Carbapenem-Resistant Acinetobacter Baumannii Infections: Study Protocol
Pharmacokinetics of a novel extended infusion regimen of fosfomycin
100 项与 磷霉素钠 相关的临床结果
登录后查看更多信息
100 项与 磷霉素钠 相关的转化医学
登录后查看更多信息
100 项与 磷霉素钠 相关的专利（医药）
登录后查看更多信息
4,512
项与 磷霉素钠 相关的文献（医药）2025-01-01Journal of Environmental Sciences
Metagenomic perspectives on antibiotic resistance genes in tap water: The environmental characteristic, potential mobility and health threat
Article
作者: He, Da ; Meng, Qiyue ; Zhang, Yibo ; Xia, Yu ; Fu, Jie ; Dang, Chenyuan
As an emerging environmental contaminant, antibiotic resistance genes (ARGs) in tap water have attracted great attention. Although studies have provided ARG profiles in tap water, research on their abundance levels, composition characteristics, and potential threat is still insufficient. Here, 9 household tap water samples were collected from the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) in China. Additionally, 75 sets of environmental sample data (9 types) were downloaded from the public database. Metagenomics was then performed to explore the differences in the abundance and composition of ARGs. 221 ARG subtypes consisting of 17 types were detected in tap water. Although the ARG abundance in tap water was not significantly different from that found in drinking water plants and reservoirs, their composition varied. In tap water samples, the three most abundant classes of resistance genes were multidrug, fosfomycin and MLS (macrolide-lincosamide-streptogramin) ARGs, and their corresponding subtypes ompR, fosX and macB were also the most abundant ARG subtypes. Regarding the potential mobility, vanS had the highest abundance on plasmids and viruses, but the absence of key genes rendered resistance to vancomycin ineffective. Generally, the majority of ARGs present in tap water were those that have not been assessed and are currently not listed as high-threat level ARG families based on the World Health Organization Guideline. Although the current potential threat to human health posed by ARGs in tap water is limited, with persistent transfer and accumulation, especially in pathogens, the potential danger to human health posed by ARGs should not be ignored.
2024-12-31Journal of medical economics
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England
Article
作者: Kennedy, Nicholas ; Ahmed, Waqas ; Pollock, Richard F ; Dhar, Anjan ; Iqbal, Tariq H
AIMS:
Anemia is the most common extraintestinal complication of inflammatory bowel disease (IBD), with approximately half of cases caused by iron deficiency (ID). Intravenous iron is the preferred ID anemia (IDA) treatment where oral iron is contraindicated, ineffective or not tolerated, or where ID correction is urgent. The objective was to evaluate the cost-utility of ferric derisomaltose (FDI) versus ferric carboxymaltose (FCM) in patients with IBD and IDA in England, in whom IV iron treatment is preferred.
MATERIALS AND METHODS:
A patient-level simulation model was developed, capturing quality of life (QoL) differences based on SF-36v2 data from the PHOSPHARE-IBD randomized controlled trial, monitoring and incidence of post-infusion hypophosphatemia, and number of iron infusions required. Analyses were conducted over a five-year time horizon from the Department of Health and Social Care (DHSC) perspective, with healthcare provider and societal perspectives adopted in separate analyses. Future costs and effects were discounted at 3.5% per annum and one-way and probabilistic sensitivity analyses were performed.
RESULTS:
FDI increased quality-adjusted life expectancy by 0.075 QALYs versus FCM from 2.57 QALYs to 2.65 QALYs per patient. Patients receiving FDI required 1.63 fewer iron infusions over the five-year time horizon, driving infusion-related cost savings of GBP 496 per patient (GBP 2,188 versus GBP 1,692) from the DHSC perspective. Costs of monitoring and treating hypophosphatemia after FCM were GBP 226, yielding total savings of GBP 722 per patient (GBP 2,414 versus GBP 1,692) over the five-year time horizon. FDI also led to reduced costs versus FCM in the societal and provider analyses and was therefore the dominant intervention across all three perspectives.
LIMITATIONS:
The analysis did not capture patient adherence, hypophosphatemic osteomalacia, or fractures.
CONCLUSIONS:
Results showed that FDI improved patient QoL and reduced direct healthcare expenditure versus FCM in patients with IBD and IDA in England.
2024-12-31Emerging microbes & infections
Prevalence and characteristics of ertapenem-mono-resistant isolates among carbapenem-resistant Enterobacterales in China
Article
作者: Jiang, Yan ; Zhao, Dongdong ; Yu, Yunsong ; Zhang, Ping ; Wang, Yinping ; Shi, Qiucheng ; Hu, Huangdu
Carbapenem-resistant Enterobacterales (CRE), specifically those resistant to only ertapenem among carbapenems (ETP-mono-resistant), are increasingly reported, while the optimal therapy options remain uncertain. To investigate the prevalence and characteristics of ETP-mono-resistant CRE, CRE strains were systematically collected from 102 hospitals across China between 2018 and 2021. A 1:1 randomized matching study was conducted with ETP-mono-resistant strains to meropenem- and/or imipenem-resistant (MEM/IPM-resistant) strains. Antimicrobial susceptibility testing, whole-genome sequencing, carbapenem-hydrolysing activity and the expression of carbapenemase genes were determined. In total, 18.8% of CRE strains were ETP-mono-resistant, with relatively low ertapenem MIC values. ETP-mono-resistant strains exhibited enhanced susceptibility to β-lactams, β-lactam/β-lactamase inhibitor combinations, levofloxacin, fosfomycin, amikacin and polymyxin than MEM/IPM-resistant strains (P < 0.05). Phylogenetic analysis revealed high genetic diversity among ETP-mono-resistant strains. Extended-spectrum β-lactamases (ESBLs) and/or AmpC, as well as porin mutations, were identified as potential major mechanisms mediating ETP-mono-resistance, while the presence of carbapenemases was found to be the key factor distinguishing the carbapenem-resistant phenotypes between the two groups (P < 0.001). Compared with the MEM/IPM-resistant group, limited carbapenemase-producing CRE (CP-CRE) strains in the ETP-mono-resistant group showed a significantly lower prevalence of ESBLs and porin mutations, along with reduced expression of carbapenemase. Remarkably, spot assays combined with modified carbapenem inactivation method indicated that ETP-mono-resistant CP-CRE isolates grew at meropenem concentrations eightfold above their corresponding MIC values, accompanied by rapidly enhanced carbapenem-hydrolysing ability. These findings illustrate that ETP-mono-resistant CRE strains are relatively prevalent and that caution should be exercised when using meropenem alone for treatment. The detection of carbapenemase should be prioritized.
100 项与 磷霉素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 子宫旁组织炎 | 韩国 | 2024-09-09 | |
| 脓毒症 | 韩国 | 2024-09-09 | |
| 菌血症 | 加拿大 | 2019-05-01 | |
| 复杂下尿路感染 | 加拿大 | 2019-05-01 | |
| 下呼吸道感染 | 加拿大 | 2019-05-01 | |
| 细菌性脑膜炎 | 加拿大 | 2019-05-01 | |
| 骨髓炎 | 加拿大 | 2019-05-01 | |
| 外耳炎 | 日本 | 1989-06-30 | |
| 中耳炎 | 日本 | 1989-06-30 | |
| 附件炎 | 日本 | 1985-01-28 | |
| 子宫内感染 | 日本 | 1985-01-28 | |
| 急性支气管炎 | 日本 | 1980-10-25 | |
| 膀胱炎 | 日本 | 1980-10-25 | |
| 脓胸 | 日本 | 1980-10-25 | |
| 出血性败血症 | 日本 | 1980-10-25 | |
| 肺脓肿 | 日本 | 1980-10-25 | |
| 腹膜炎 | 日本 | 1980-10-25 | |
| 肺炎 | 日本 | 1980-10-25 | |
| 肾盂肾炎 | 日本 | 1980-10-25 | |
| 继发感染 | 日本 | 1980-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 复杂的尿路感染 | 申请上市 | 爱尔兰 | 2022-01-30 | |
| 复杂腹腔感染 | 临床1期 | 爱尔兰 | 2022-01-30 | |
| 医院获得性肺炎 | 临床1期 | 爱尔兰 | 2022-01-30 | |
| 细菌性肺炎 | 临床1期 | 爱尔兰 | 2022-01-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 39 | 鬱襯觸齋選選鏇鹹鏇襯(選淵餘醖選鏇選襯選餘) = 繭選衊構鏇簾窪顧鬱衊 選壓壓蓋觸簾簾繭鬱壓 (蓋構壓選願餘鏇鹽廠鏇, 製積獵糧獵鹹願壓遞簾 ~ 淵憲製繭齋窪醖網鹹廠) 更多 | - | 2022-01-19 | |||
临床2/3期 | 465 | (ZTI-01) | 鬱鹹衊糧艱醖壓構鏇艱(製獵製簾鑰鬱窪壓膚衊) = 簾鹹願衊膚憲選膚憲壓 簾餘觸蓋積築憲憲憲膚 (積憲選築壓鑰憲積夢選, 簾製製膚選憲鬱獵願鬱 ~ 蓋窪膚製遞蓋夢窪齋簾) 更多 | - | 2018-12-11 | ||
(Piperacillin Tazobactam) | 鬱鹹衊糧艱醖壓構鏇艱(製獵製簾鑰鬱窪壓膚衊) = 窪積顧糧襯鑰淵鬱範憲 簾餘觸蓋積築憲憲憲膚 (積憲選築壓鑰憲積夢選, 選醖衊繭製齋構獵獵窪 ~ 壓顧艱鬱觸繭觸鹽簾糧) 更多 | ||||||
N/A | 15 | Fosfomycin IV | 壓醖夢憲積壓選選積構(簾醖繭壓壓襯願簾窪獵) = Only 1 had nausea 蓋齋觸積餘願膚獵夢製 (蓋遞淵鏇廠糧廠製艱醖 ) 更多 | - | 2018-09-15 | ||
N/A | - | 構齋糧簾夢餘鏇構選築(簾鏇鏇選鹽齋構襯簾襯) = 積構遞夢餘醖選衊觸夢 鹹鹹壓襯衊憲鏇窪構範 (艱觸膚遞餘憲廠範製簾 ) 更多 | - | 2015-11-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用